A 90-day marketing plan to own the metabolic health conversation online and drive high-intent traffic directly to your link.
US adult awareness of GLP-1 medications
Projected obesity drug market by 2030 (Goldman Sachs). JP Morgan projects the broader incretin/GLP-1 market at $200B+.
of people in Facebook weight loss and mom groups asking questions daily
Hers, TrimRx, Eden, and Mochi have proved demand exists. None have built the compliance-grade content machine to own it long-term. Tens of millions of women are in Facebook weight loss groups, postpartum communities, and mom groups every single day. They are looking for answers. The window to own that conversation is right now, before a better-capitalized operator builds what we are building.
They run a few paid ads, post inconsistently, and hope the algorithm finds them. The brands that win run real marketing operations at a scale most operators cannot match. Hims & Hers spent $919 million on marketing in fiscal 2025 (39% of revenue), then ran their second consecutive Super Bowl spot in February 2026 at a reported $16 million for one 60-second placement. Ro followed with its own Super Bowl ad featuring Serena Williams. The duopoly at the top of paid acquisition has compressed creative diversity in the entire category, every paid feed in this vertical now looks like Hims. Most telehealth platforms cannot afford to spend nine figures, so they are renting attention they can never own. The answer is not a bigger ad budget. It is a content machine that builds owned attention compounding at scale.
Not an agency. Not a media buyer. A machine that takes a topic, tests content until it finds what converts, then floods every relevant channel until the algorithm has no choice but to reward it. We have done this across music, apps, brands, and media. Now we do it in health, on Facebook and Instagram first, TikTok second.
Managed catalog distribution across Facebook, YouTube, Instagram, and TikTok. Coordinated drops that drove 1B+ streams. The same cross-platform coordination architecture we use for health content.
Took apps from zero users to scale through organic content flooding and coordinated growth. Built content machines for consumer businesses without in-house marketing teams.
Built listenership growth engines for podcasters using Facebook and Instagram distribution. Media brands taken from niche to dominant through coordinated content velocity.
Distribution wins. We do not guess what will work. We run aggressive signal tests on Meta and TikTok, identify the creative angles and audience segments that convert, then flood those angles simultaneously across paid channels and our account network. The machine does not stop. Every week it gets sharper.
Facebook users have seen every hard-sell health ad. The content that converts is the hard-but-soft sell: curiosity first, education second, aspiration third, soft offer last. Engaging enough to stop the scroll. Compliant enough to never get flagged.


Facebook and Instagram feed posts
Meta Reels and TikTok short-form video


100+ accounts distributing across all topics simultaneously
FDA-aware. FTC-compliant. Platform-native. Built to convert without crossing lines that kill distribution.
AI-assisted pipeline producing 40-60 finished assets per week across video, static, and carousel. Continuous monitoring of top-performing content in the Meta Ad Library and organic feeds.
Account infrastructure across Facebook, Instagram, and TikTok. Real-device architecture that survives platform throttling. Scales to 500+ active accounts across topics.
Meta Ads and TikTok ad accounts with full attribution stack. Weekly reporting cadence. Performance gates and kill switches throughout the 90-day run.
Distribution without measurement is gambling. Every account, post, ad, and conversion is tracked in real time. Weekly performance reviews compare actual results against targets, and underperforming creative or audiences get cut immediately. Targets below are starting benchmarks. They tighten as the network compounds and CAC drops.
Targets tighten week over week as the network compounds. Phase 2 and Phase 3 unlock only on Phase 1 metric clearance.
Every metric above lives in a single client dashboard updated continuously. Partners get login access from Day 1. We do not produce monthly summary reports. The dashboard is always live, always current. Weekly performance reviews are conducted against this view. There is no version of this where we say results are pending.
Your team receives dashboard access on Day 1. We do not gatekeep performance data.
Priority segments identified through category research and conversion data. Each segment has its own creative system.
People who want to lose weight without going to the gym. Diet failures, schedule constraints, exercise aversion. The honest framing: change without forcing the workout. Lifestyle bridge, not lifestyle prescription.
Women within a year of having a baby. Hormone shifts, metabolic disruption, identity recovery. High intent, low time, high spend ceiling. Dramatically underserved by general weight-loss messaging.
Men 35-55, biohacker-adjacent, Bryan Johnson and Brecka follower base. Education-led content, mechanism explanations, not outcome claims.
25-45, gym + recovery focused, peptide Twitter literate. Soft-sell expertise content.
35-65, premium spend, Goop-adjacent. Aspirational + scientific framing. Celebrity halo without endorsement.
Already using GLP-1 elsewhere or starting now. Cross-sell into adjacent SKUs. Funnel deepening, not acquisition.
The category is in active enforcement, and the timing is now. The FDA declared the semaglutide shortage resolved on February 21, 2025, and the enforcement discretion window for compounded semaglutide expired in spring 2026. In September 2025, the FDA and HHS launched a major initiative, over 55 warning letters and thousands of cease-and-desist letters targeting deceptive direct-to-consumer pharmaceutical advertising. In February 2026, the FDA escalated with 30 additional warning letters specifically to telehealth companies marketing compounded GLP-1s. Hims received one of the September letters for marketing language stating its compounded products had "the same active ingredient as Wegovy, and Ozempic," language the FDA called misleading because it implied an FDA approval that does not exist. NextMed paid the FTC $150K in July 2025 for hidden subscription terms, fabricated weight-loss claims, fake reviews and testimonials, and review suppression. Operators without compliance discipline are getting taken out. Operators who survive will own the category.
Paid media is rented attention. The accounts we build keep sending traffic to the link without additional spend. Paid media stops the moment you stop paying. Our accounts do not. Each account survives if a single one gets throttled. Each one compounds. No competitor can replicate this quickly because building authentic niche accounts at scale requires both the infrastructure to operate them and the creative discipline to make them indistinguishable from organic operators. We have both.
| Line item | Detail | Amount |
|---|---|---|
| Paid media (Meta + TikTok) | 70/30 split, geo-locked, phased release | $9,000 |
| Creative production | 40-60 compliance-safe assets, Phase 1 alone | $4,000 |
| Real UGC creators | 6-8 paid creator pieces with FTC disclosures | $2,500 |
| Distribution platform build | Account infrastructure, multi-platform setup | $2,000 |
| Compliance consultant | Per-asset review, claim library development | $1,500 |
| Healthcare attorney | Retainer, agreement review, partnership structure | $1,000 |
| Total Phase 1 | $20,000 |
Phase 2 and Phase 3 budgets unlock on gate clearance. Performance-gated through the full 90 days.
Next step: align on Phase 1 launch and activate within 30 days.
Mid-Day Media · Demand Generation Plan · Confidential · Not for distribution